Zannel Blanchard
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zannel Blanchard has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Jason Gertz
Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah 84112, USA
73 shared publications - Craig M. Rush
Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah 84112, USA
72 shared publications - David H. Lum
Preclinical Research Resource, Huntsman Cancer Institute, University of Utah
72 shared publications - Spencer Arnesen
Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
72 shared publications - Jeffery M. Vahrenkamp
Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah 84112, USA
71 shared publications - Adriana Cristina Rodriguez
Department of Neurobiology, University of Utah, Salt Lake City, UT, USA
70 shared publications
Latest Publications
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 4 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
ER mutants do not affect proliferation, but down-regulate proteins associated with movement and impact migration
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 4 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
ER mutants do not affect proliferation, but down-regulate proteins associated with movement and impact migration
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 6 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
Identification of novel therapeutic targets in ER active and mutant endometrial cancer
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 6 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
Identification of novel therapeutic targets in ER active and mutant endometrial cancer
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 5 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
Enrichment values for ER associating proteins in endometrial and breast cancer cell lines
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 5 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
Enrichment values for ER associating proteins in endometrial and breast cancer cell lines
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
Validation and gene expression analysis of ER mutant models
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
Validation and gene expression analysis of ER mutant models
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
Comparison of mutant ER regulated genes and genes regulated by sustained estrogen signaling
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
Comparison of mutant ER regulated genes and genes regulated by sustained estrogen signaling
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 4 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
Mutant ESR1 generation: gBlock used for template amplification
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 4 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
Mutant ESR1 generation: gBlock used for template amplification
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
Differentially expressed genes from in vitro RNA-seq experiments
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
Differentially expressed genes from in vitro RNA-seq experiments
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 2 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
Overlap between prolonged E2 treatment and differentially expressed genes in vitro
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 2 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
Overlap between prolonged E2 treatment and differentially expressed genes in vitro
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 3 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
Differentially expressed genes from in vivo RNA-seq experiments
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 3 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
Differentially expressed genes from in vivo RNA-seq experiments
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 5 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
ER-Y537S and ER-D538G mutants drive proliferative gene expression signatures in vivo
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 5 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
ER-Y537S and ER-D538G mutants drive proliferative gene expression signatures in vivo